Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Sarepta options CMT gene therapy candidate from NCH

Executive Summary

Sarepta Therapeutics Inc. gained an exclusive option to Nationwide Children's Hospital's neurotrophin 3 (NT-3) gene therapy candidate for Charcot-Marie-Tooth (CMT) disease, a group of rare, inherited, degenerative motor and sensory neuropathies that affects the peripheral nerves and can lead to muscle wasting and numbness.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register